Press Release

CancerCare^® Announces Funding for Thyroid Cancer Patients Through CancerCare Co-Payment Assistance Foundation (CCAF)

NEW YORK (August 11, 2016) — CancerCare is pleased to announce the availability of co-payment assistance for people diagnosed with metastatic differentiated thyroid cancer through the CancerCare Co-Payment Assistance Foundation. CancerCare is the leading national nonprofit organization providing free, professional support services to anyone affected by cancer.

Co-payment assistance through this fund is available to people coping with metastatic differentiated thyroid cancer that is radioactive iodine refractory (no longer responding to radioactive iodine treatment). This funding is limited to patients with insurance through a federal health care program such as Medicare.

The CancerCare Co-Payment Assistance Foundation (CCAF) is dedicated to helping people with cancer meet what otherwise are significant co-payment obligations for cancer treatment. CCAF is authorized to provide co-payment assistance for all types of cancer. This assistance is provided to ensure that patients have access to care and prescribed treatments.

People receiving assistance from CCAF also have immediate, ongoing access to the full array of CancerCare services, including counseling, support groups (online, telephone and in-person), resource referrals, publications, education and financial assistance with treatment-related expenses such as transportation and child care. The robust network of support services offered by CancerCare can have a significant impact on the patient, as well as the entire family.

“We are thrilled to provide this crucial co-payment assistance to people coping with metastatic differentiated thyroid cancer,” said Patricia J. Goldsmith, CancerCare Chief Executive Officer. “The CancerCare Co-Payment Assistance Foundation is committed to helping patients access the care they need so that they can focus on managing their diagnosis and maintaining quality of life during treatment.”

The American Cancer Society estimates that over 60,000 individuals will be newly diagnosed with thyroid cancer, a cancer of the thyroid gland, in 2016, with the majority of thyroid cancers being differentiated cancers. This funding will enable CCAF to continue providing much-needed, comprehensive assistance to patients who are struggling to meet their coinsurance obligations, which may enable them to adhere to their prescribed treatments and potentially help to improve their outcomes.

To qualify for assistance, patients diagnosed with metastatic differentiated thyroid cancer must meet certain financial and insurance criteria. For more information, or to apply for assistance, patients and healthcare professionals can visit the CCAF portal at portal.cancercarecopay.org or call 866-55-COPAY (866-552-6729). CCAF’s Co-Payment Specialists are available to take calls Monday through Thursday from 9 a.m. to 7 p.m. EST, and Friday from 9 a.m. to 5 p.m. EST.

About CancerCare^®

Founded in 1944, CancerCare is the leading national organization providing free, professional support services and information to help people manage the emotional, practical and financial challenges of cancer. Our comprehensive services include counseling and support groups over the phone, online and in-person, educational workshops, publications and financial and co-payment assistance. All CancerCare services are provided by oncology social workers and world-leading cancer experts. Headquartered in New York, NY, CancerCare maintains three additional locations in Norwalk, CT, Ridgewood, NJ and Syosset, NY.

To learn more, visit www.cancercare.org or call 800-813-HOPE (4673).

Back to Press Releases